N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models

International Journal of Cancer

Volumn 67, Issue 6, 1996, Pages 821-825

  Jansen, Burkhard ^a,b   Inoue, Sue A ^a,b   Wadl, Hermine ^a,b   Eichler, Hans Georg ^a   Wolff, Klaus ^b   Van Elsas, Andrea ^c   Schrier, Peter I ^c   Pehamberger, Hubert ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Division of General Dermatology   (Austria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; MELANOMA; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; GENE EXPRESSION; GENES, RAS; HUMANS; MELANOMA; MICE; MICE, SCID; MUTATION; ONCOGENE PROTEIN P21(RAS); TRANSPLANTATION, HETEROLOGOUS;

EID: 0029926502     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960917)67:6<821::AID-IJC11>3.0.CO;2-4     Document Type: Article

References (24)

1. AHERN, T.E., BIRD, R.C., BIRD, A.E. and WOLFE, L.G., Overexpression of c-erbB-2 and c-myc but not c-ras, in canine melanoma cell lines, is associated with metastatic potential in nude mice. Anticancer Res., 13, 1365-1371 (1993).
2. ALBINO, A.P. and FOUNTAIN, J.W., Molecular genetics of human malignant melanoma. In: L. Nathanson (ed.), Current research and clinical management of melanoma, pp. 201-255, Kluwer, Dordrecht (1993).
3. ALBINO, A.P., LE STRANGE, R., OLIFF, A.I., FURTH, M.E. and OLD, L.J., Transforming ras genes from human melanoma: a manifestation of tumor heterogeneity? Nature (Lond.), 308, 69-72 (1984).
4. BALL, N.F., YOHN, J.J., MORELLI, J.G., NORRIS, D.A., GOLITZ, L.E. and HOEFFLER, J.P., Ras mutations in human melanoma: a marker of malignant progression. J. invest. Dermatol., 102, 285-290 (1994).
5. BARBACID, M., Ras genes. Ann. Rev. Biochem., 56, 779-827 (1987).
6. BOS, J.L., Ras oncogenes in human cancer: a review. Cancer Res., 49, 4682-4689 (1989).
7. BOSMA, G.C., CUSTER, R.P. and BOSMA, M.J., A severe combined immunodeficiency in the mouse. Nature (Lond.), 301, 527-530 (1983).
8. HALL, A. and BROWN, R., Human N-ras: cDNA cloning and gene structure. Nucl. Acids Res., 13, 5255-5268 (1985).
9. HILL, L.L., KORNGOLD, R., JAWORSKY, C., MURPHY, G., MCCUE, P. and BERD, D., Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency. Cancer Res., 51, 4937-4941 (1991).
10. JANSEN, B., WADL, H., INOUE, S.A., TRÜLZSCH, B., SELZER, E., DUCHENE, M., EICHLER, H.-G., WOLFF, K. and PEHAMBERGER, H., Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a non-antisense mechanism. Antisense Res. Devel., 5, 271-277 (1995).
11. KINOSHITA, T., YOKATA, T., ARAI, K. and MIYAJIMA, A., Regulation of Bcl-2 expression by oncogenic ras protein in hematopoietic cells. Oncogene, 10, 2207-2212 (1995).
12. LOWY, D.R. and WILLUMSEN, B.M., Function and regulation of ras. Ann. Rev. Biochem., 62, 851-891 (1993).
13. MCCORMICK, F., How receptors turn ras on. Nature (Lond.), 363, 15-16 (1993).
14. NOOTER, K., BOERSMA, A.W., OOSTRUM, R.G., BURGER, H., JOCHEMSEN, A.G. and STOTER, G., Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Brit. J. Cancer, 71, 556-561 (1995).
15. PELTENBURG, L.T.C., DEE, R. and SCHRIER, P.I., Downregulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A. Nucl. Acids Res., 21, 1179-1185 (1993).
16. RAK, I., MITSUHASHI, Y., BAYKO, L., FILMUS, J., SHIRASAWA, S., SASAZUKI, T. and KERBEL, R.S., Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55, 4575-4580 (1995).
17. RAYBAUD, F., NOGUCHI, T., MARICS, I., ADELAIDE, J., PLANCHE, J., BATOZ, M., AUBERT, C., DE LAPEYRIERE, O. and BIRNBAUM, D., Detection of a low frequency of activated ras genes in human melanomas using a tumorigenicity assay. Cancer Res., 48, 950-953 (1988).
18. SCHRIER, P.I., VERSTEEG, R., PELTENBURG, L.T.C., PLOMP, A.C., VAN'T VEER, L.J. and KRUSE-WOLTERS, K.M., Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin. Cancer Biol., 2, 73-83 (1991).
19. SHUKLA, V.K., HUGHES, D.C., HUGHES, L.E., MCCORMICK, F. and PADUA, R.A., Ras mutations in human melanocytic lesions - K-ras activation is a frequent and early event in melanoma development. Oncogene Res., 5, 121-127 (1989).
20. VAN ELSAS, A., VAN DER MINNE, C.E., MOURER, J.S., KAST, W.M., MELIEF, C.J.M. and SCHRIER, P.I., Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int. J. Cancer, 61, 389-396 (1995a).
21. VAN ELSAS, A., VAN DEURSEN, E., WIELDERS, R., VAN DEN BERG-BAKKER, C.A.M. and SCHRIER, P.I., Ras oncogene activation does not induce sensitivity to natural killer cell-mediated lysis in human melanoma. J. invest. Dermatol., 103, 117s-121s (1994).
22. VAN ELSAS, A., ZERP, S., VAN DER FLIER, S., KRUSE-WOLTERS, M., VACCA, A., RUITER, D.J. and SCHRIER, P., Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. Rec. Results Cancer Res., 139, 57-67 (1995b).
23. VAN'T VEER, L.J., BURGERING, B.M., VERSTEEG, R., BOOT, A.J.M., RUITER, D.J., OSANTO, S., SCHRIER, P.I. and BOS, J.L., N-ras-mutations in human cutaneous melanoma on sun-exposed body sites. Mol. cell. Biol., 9, 3114-3116 (1989).
24. VERSTEEG, R., PELTENBURG, L.T.C., PLOMP, A.C. and SCHRIER, P.I., High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells. J. Immunol., 143, 4331-4337 (1989).